LY-320,135
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | 176977-56-3 |
| PubChem (CID) | 5311257 |
| IUPHAR/BPS | 742 |
| ChemSpider | 4470772 |
| UNII | CJY03984CT |
| ChEMBL | CHEMBL411481 |
| ECHA InfoCard | 100.190.302 |
| Chemical and physical data | |
| Formula | C24H17NO4 |
| Molar mass | 383.395 |
| 3D model (Jmol) | Interactive image |
| |
| |
| (verify) | |
LY-320,135 is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1. It was developed by Eli Lilly and Company in the 1990s.
LY-320,135 displays fairly good selectivity, with a binding affinity for CB1 around 70x stronger than for CB2,[1] but both its potency and selectivity are modest compared to newer agents, and at higher doses it also binds to a range of non-cannabinoid receptors. However LY-320,135 is still fairly widely used in research, particularly for elucidating the mechanisms by which many CB1 antagonists act as inverse agonists at higher doses.[2]
References
- ↑ Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chaney MO, Koppel GA, Brownstein M. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. Journal of Pharmacology and Experimental Therapeutics. 1998 Jan;284(1):291-7. PMID 9435190
- ↑ Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sciences. 2005 Feb 4;76(12):1307-24. PMID 15670612
This article is issued from Wikipedia - version of the 5/6/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.